ImmunityBio, Inc. (NASDAQ: IBRX)

This lawsuit is for anyone who acquired securities in ImmunityBio, Inc. (NASDAQ: IBRX) from January 19, 2026 through March 24, 2026.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors when the Company’s Executive Chairman went on a podcast and falsely stated the Company’s lead biologic product, Anktiva, could cure and prevent all cancers.

On March 24, 2026, Bloomberg reported that ImmunityBio had receive a Warning Letter from the U.S. Food and Drug Administration (“FDA”) stating that the Company’s Executive Chairman and Global Chief Scientific and Medical Officer, Patrick Soon-Shiong, made inaccurate claims on a podcast regarding the Company’s lead biologic product, Anktiva, including that the drug “can cure and even prevent all cancer.” The FDA thus “determined that the TV ad and podcast are false or misleading” and “make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in ImmunityBio, Inc. (NASDAQ: IBRX) from January 19, 2026 through March 24, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.